Article
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.
Cancer communications (London, England) - 1 Jan 2023
Yang Hang, Zhou Xinyi, Fu Dongliang, Le Chenqin, Wang Jiafeng, Zhou Quan, Liu Xiangrui, Yuan Ying, Ding Kefeng, Xiao Qian
Abstract excerpt
RAS genes are the most frequently mutated oncogenes and play critical roles in the development and progression of malignancies. The mutation, isoform (KRAS, HRAS, and NRAS), position, and type of substitution vary depending on the tissue types. Despite decades of developing RAS-targeted therapies, only small subsets of these inhibitors are clinically effective, such as the allele-specific inhibitors against...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.